- Cohance Lifesciences shares surged nearly 40% in two trading days to Rs 507
- Stock hit upper circuit of 20% consecutively on Monday and Tuesday
- Growth momentum follows appointment of Umang Vohra as Chairman and Group CEO
Shares of Cohance Lifesciences have been on a roll in the last two trading days. After hitting upper circuit of 20% on Monday, the pharmaceutical stock is once again hovering around another upper circuit on Tuesday, as confidence around the company continues to grow after a key appointment.
The stock is currently trading at Rs 507, accounting for gains of more than 17%. In the last two days, the stock has surged almost 40%, rising from Friday's close of Rs 360 to current levels in no time.
The positive momentum in Cohance Lifesciences largely comes on the back of Umang Vohra's appointment as its Chairman and Group CEO.
Former Cipla chief Umang Vohra, one of the most recognised leaders in India's pharmaceutical industry, will be tasked with steering the contract development and manufacturing organisation (CDMO) through its next phase of growth.
Vohra served as Managing Director and Global CEO of Cipla from 2016 until March 31, 2026, during which he was instrumental in reshaping the company's strategic direction.
Under his leadership, Cipla transitioned from a volume-led generics player to a higher-value pharmaceutical company, moving away from commodity products toward complex and specialty offerings, particularly in respiratory and chronic therapies built around differentiated, high-entry-barrier portfolios.
ALSO READ: Cohance Lifesciences Shares In Focus: Here's Why The Former Cipla Top Boss Is A Strategic Fit
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.